Advertisement

Neuroscience and Behavioral Physiology

, Volume 49, Issue 1, pp 142–146 | Cite as

Biomarkers for Cerebral Ischemia as a Novel Method for Validating the Efficacy of Neurocytoprotectors

  • S. A. Dambinova
  • K. T. Aliev
  • E. V. Bondarenko
  • G. V. Ponomarev
  • A. A. SkorometsEmail author
  • A. P. Skoromets
  • T. A. Skoromets
  • D. G. Smolko
  • M. V. Shumilina
Article
  • 2 Downloads

Objectives. To assess the diagnostic value of NR2 peptide as a biomarker for cerebral ischemia by studying its plasma concentration in patients with ischemic stroke (IS) and to determine changes in levels due to treatment with the low molecular weight neuroprotector Cortexin. Materials and Methods. A total of 120 patients aged 18–70 years were studied, of which 36 were diagnosed with transient ischemic attacks (TIA) and 84 with IS – 70 in the carotid basin and 14 in the vertebrobasilar basin with Wallenberg–Zakharchenko syndrome. Determination of neurological status included assessment on the NIHSS stroke scale. Plasma NR2 concentrations were estimated in all patients on admission and after courses of treatment and results were compared with CT and MRI neuroimaging studies. Results and Conclusions. NR2 peptide fragment concentrations in all patients were above the normal value (>1.5 ng/ml, p < 0.0001). A direct correlation was found between the concentration of NR2 peptide (from 3.38 ng/ml to 15.6 ng/ml) and the size of the ischemia zone from a few mm to 80 mm (rs = 0.73). After 10-day courses of treatment with Cortexin, NR2 peptide fragment concentrations decreased (from 8.5 to 5.9 ng/ml, p < 0.0001). These data lead to the conclusion that this blood test for cerebral ischemia is valid and that Cortexin has significant therapeutic efficacy.

Keywords

stroke diagnosis biomarker for cerebral ischemia NR2 peptide treatment Cortexin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. J. Hand, J. Kwan, R. I. Lindley, M. S. Dennis, and J. M. Wardlaw, “Distinguishing between stroke and mimic at the bedside: the brain attack study,” Stroke, 37, 769–775 (2006), doi:  https://doi.org/10.1161/01.STR.0000204041.13466.4c.CrossRefPubMedGoogle Scholar
  2. 2.
    T. M. Hemmen, B. C. Meyer, T. L. McClean, and P. D. Lyden, “Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center,” J. Stroke Cerebrovasc. Dis., 17, 23–25 (2008), doi:  https://doi.org/10.1016/j.strokecerebrovasdis.2007.09.008. CrossRefPubMedGoogle Scholar
  3. 3.
    P. C. Vroomen, M. K. Buddingh, G. J. Luijckx, and J. De Keyser, “The incidence of stroke mimics among stroke department admissions in relation to age group,” J. Stroke Cerebrovasc. Dis., 17, 418–422 (2008), doi:  https://doi.org/10.1016/j.strokecerebrovasdis.2008.06.007. CrossRefPubMedGoogle Scholar
  4. 4.
    R. von Kummer, P. N. Nolte, H. Schnittger, A. Thron, and E. B. Ringelstein, “Detectability of cerebral hemisphere ischemic infarcts by CT within 6 h of stroke,” Neuroradiology, 38, 31–33 (1996).CrossRefGoogle Scholar
  5. 5.
    P. J. Hand, J. M. Wardlaw, A. M. Rowat, J. A. Haisma, R. I. Lindley, and M. S. Dennis, “Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient related difficulties,” J Neurol. Neurosurg. Psychiatry, 76, 1525–1527 (2005), doi:  https://doi.org/10.1136/jnnp.2005.062539. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    C. Warlow, C. Sudlow, M. Dennis, J. Wardlaw, and P. Sandercock, “Stroke,” Lancet, 362, 1211–1224 (2003), doi:  https://doi.org/10.1016/S0140-6736(03)14544-8.CrossRefPubMedGoogle Scholar
  7. 7.
    K. L. Furie, S. E. Kasner, R. J. Adams, et al., “Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, 42, 227–276 (2011), doi:  https://doi.org/10.1161/STR.0b013e3181f7d043. CrossRefPubMedGoogle Scholar
  8. 8.
    W. Whiteley, M. C. Tseng, and P. Sandercock, “Blood biomarkers in the diagnosis of ischemic stroke. A systematic review,” Stroke, 39, 2902–2909 (2008), doi:  https://doi.org/10.1161/STROKEAHA.107.511261. CrossRefPubMedGoogle Scholar
  9. 9.
    K. Bettermann, “Biomarkers for stroke: in search of fingerprints,” J. Stroke Cerebrovasc. Dis., 20, 173–176 (2011), doi:  https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.02.003.CrossRefPubMedGoogle Scholar
  10. 10.
    C. Betzen, R. White, C. M. Zehendner, E. Pietrowski, B. Bender, H. J. Luhmann, and R. W. Kuhlmann, “Oxidative stress upregulates the NMDA receptor on cerebrovascular endothelium,” Free Radic. Biol. Med., 47, 1212–1220 (2009), doi:  https://doi.org/10.1016/j.freeradbiomed.2009.07.034.CrossRefPubMedGoogle Scholar
  11. 11.
    C. D. Sharp, M. Fowler, T. H. Jackson, et al., “Human neuroepithelial cells express NMDA receptors,” BMC Neurosci., 4, 28–32 (2003), doi:  https://doi.org/10.1186/1471-2202-4-28. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    S. A. Dambinova, “Biomarkers for transient ischemic attack and ischemic stroke,” Clin. Lab. Int., 32, 7–10 (2008).Google Scholar
  13. 13.
    M. U. Gappoeva, G. A. Izykenova, O. K. Granstrem, and S. A. Dambinova, “NMDA receptor mRNA expression in experimental ischemia,” Biokhimiya, 68, 696–702 (2003), doi:  https://doi.org/10.1023/A:1024678112357. CrossRefGoogle Scholar
  14. 14.
    A. A. Skoromets, A. P. Skoromets, and T. A. Skoromets, Topical Diagnosis of Nervous System Diseases. Guidelines for Doctors, Politekhnika, St. Petersburg (2014), 9th ed.Google Scholar
  15. 15.
    H. Barry, S. Byrne, E. Barrett, K. C. Murphy, and D. R. Cotter, “Anti-N-methyl-D-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment,” BJPsych. Bull., 39, 19–23 (2015), doi:  https://doi.org/10.1192/pb.bp.113.045518.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    S. A. Dambinova, A. A. Skoromets, and A. P. Skoromets, Biomarkers for Cerebral Ischemia (development, investigations, and practical aspects), IPK Kosta Ltd., St. Petersburg (2013).Google Scholar
  17. 17.
    J. D. Weissman, G. A. Khunteev, R. Heath, and S. A. Dambinova, “NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events,” J. Neurol. Sci., 300, 97–102 (2011), doi:  https://doi.org/10.1016/j.jns.2010.09.023.CrossRefPubMedGoogle Scholar
  18. 18.
    L. V. Stakhovskaya, K. S. Meshkova, M. N. Dadasheva, et al., “A multicenter, randomized, prospective, double-blind, placebo-controlled trial of the safety and efficacy of Cortexin in the acute and early recovery periods of hemispheric ischemic stroke,” Vestn. Ross. Voenno-Med. Akad., 37, No. 1, 238–244 (2012).Google Scholar
  19. 19.
    M. M. Tanashyan, D. Yu. Barkhatova, N. A. Glotova, et al., “Efficacy of neuroprotection in patients with chronic cerebrovascular diseases,” Vestn. Ross. Voenno-Med. Akad., 35, No. 3, 181–187 (2011).Google Scholar
  20. 20.
    A. A. Skoromets, A. P. Skoromets, and T. A. Skoromets, Neurological Status and its Interpretation. Guidelines for Doctors, M. M. D’yakonov (ed.), MEDpress-inform, Moscow (2010).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • S. A. Dambinova
    • 1
  • K. T. Aliev
    • 1
  • E. V. Bondarenko
    • 1
  • G. V. Ponomarev
    • 1
  • A. A. Skoromets
    • 1
    Email author
  • A. P. Skoromets
    • 1
  • T. A. Skoromets
    • 1
  • D. G. Smolko
    • 1
  • M. V. Shumilina
    • 1
  1. 1.Research Institute of Neurology, Pavlov First St. Petersburg State Medical UniversityRussian Ministry of HealthSt. PetersburgRussia

Personalised recommendations